Details of the Drug

General Information of Drug (ID: DMM0XGL)

• Drug Name: Idarubicin
• Synonyms: DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1], [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 497.5
  Topological Polar Surface Area (xlogp); 1.9
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 5
  Hydrogen Bond Acceptor Count (hbondacc); 10
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 24 mL/min/kg [4]
  Elimination: 3% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 22 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.42707 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.076% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 38 L/kg [4]
• Chemical Identifiers:
  Formula: C26H27NO9
  IUPAC Name: (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
  Canonical SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
  InChI: InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
  InChIKey: XDXDZDZNSLXDNA-TZNDIEGXSA-N
• Cross-matching ID:
  PubChem CID: 42890
  ChEBI ID: CHEBI:42068
  CAS Number: 58957-92-9
  DrugBank ID: DB01177
  TTD ID: D01XDL
  VARIDT ID: DR00386
  INTEDE ID: DR0852

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[7]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Idarubicin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[59]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Midostaurin.	Acute myeloid leukaemia [2A60]	[60]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Arn-509.	Acute myeloid leukaemia [2A60]	[61]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[62]

Coadministration of a Drug Treating the Disease Different from Idarubicin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[63]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Oliceridine.	Acute pain [MG31]	[60]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Idarubicin and Ivabradine.	Angina pectoris [BA40]	[61]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Bepridil.	Angina pectoris [BA40]	[60]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Dronedarone.	Angina pectoris [BA40]	[60]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[64]
Posaconazole	DMUL5EW	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Posaconazole.	Aspergillosis [1F20]	[63]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Levalbuterol.	Asthma [CA23]	[65]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Idarubicin and Pirbuterol.	Asthma [CA23]	[66]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Roflumilast.	Asthma [CA23]	[61]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[61]
Clarithromycin	DM4M1SG	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[63]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[67]
ABT-492	DMJFD2I	Minor	Decreased absorption of Idarubicin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[68]
Retigabine	DMGNYIH	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Retigabine.	Behcet disease [4A62]	[63]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[69]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Eribulin.	Breast cancer [2C60-2C6Y]	[60]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[63]
HKI-272	DM6QOVN	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by HKI-272.	Breast cancer [2C60-2C6Y]	[63]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[63]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[63]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[70]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[66]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[65]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Idarubicin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[66]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[66]
Ulipristal	DMBNI20	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Ulipristal.	Contraceptive management [QA21]	[63]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Sevoflurane.	Corneal disease [9A76-9A78]	[60]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Probucol.	Coronary atherosclerosis [BA80]	[60]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Pasireotide.	Cushing syndrome [5A70]	[60]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Osilodrostat.	Cushing syndrome [5A70]	[61]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[63]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Clomipramine.	Depression [6A70-6A7Z]	[60]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[60]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Idarubicin and Deutetrabenazine.	Dystonic disorder [8A02]	[71]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Idarubicin and Ingrezza.	Dystonic disorder [8A02]	[72]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Solifenacin.	Functional bladder disorder [GC50]	[60]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[60]
Boceprevir	DMBSHMF	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Boceprevir.	Hepatitis virus infection [1E50-1E51]	[63]
Telaprevir	DMMRV29	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Telaprevir.	Hepatitis virus infection [1E50-1E51]	[63]
Daclatasvir	DMSFK9V	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Daclatasvir.	Hepatitis virus infection [1E50-1E51]	[63]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[73]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[74]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Idarubicin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[75]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[63]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[63]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Idarubicin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[61]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Denosumab.	Low bone mass disorder [FB83]	[76]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Crizotinib.	Lung cancer [2C25]	[77]
Brigatinib	DM7W94S	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Brigatinib.	Lung cancer [2C25]	[63]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Ceritinib.	Lung cancer [2C25]	[60]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Osimertinib.	Lung cancer [2C25]	[78]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[63]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Selpercatinib.	Lung cancer [2C25]	[61]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Lumefantrine.	Malaria [1F40-1F45]	[79]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Halofantrine.	Malaria [1F40-1F45]	[80]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Hydroxychloroquine.	Malaria [1F40-1F45]	[81]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[61]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[63]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Vemurafenib.	Melanoma [2C30]	[60]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and LGX818.	Melanoma [2C30]	[82]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[83]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Panobinostat.	Multiple myeloma [2A83]	[84]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Tecfidera.	Multiple sclerosis [8A40]	[85]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Idarubicin and Siponimod.	Multiple sclerosis [8A40]	[79]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Idarubicin and Fingolimod.	Multiple sclerosis [8A40]	[86]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Ocrelizumab.	Multiple sclerosis [8A40]	[87]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Idarubicin and Ozanimod.	Multiple sclerosis [8A40]	[61]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Romidepsin.	Mycosis fungoides [2B01]	[60]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[60]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[88]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[89]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[90]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Entrectinib.	Non-small cell lung cancer [2C25]	[79]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[61]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Lofexidine.	Opioid use disorder [6C43]	[60]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Rucaparib.	Ovarian cancer [2C73]	[60]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Triclabendazole.	Parasitic worm infestation [1F90]	[60]
Istradefylline	DM20VSK	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Istradefylline.	Parkinsonism [8A00]	[63]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Pimavanserin.	Parkinsonism [8A00]	[91]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[92]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Lefamulin.	Pneumonia [CA40]	[93]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Degarelix.	Prostate cancer [2C82]	[61]
ABIRATERONE	DM8V75C	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by ABIRATERONE.	Prostate cancer [2C82]	[63]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Enzalutamide.	Prostate cancer [2C82]	[61]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Relugolix.	Prostate cancer [2C82]	[61]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[60]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Canakinumab.	Rheumatoid arthritis [FA20]	[94]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Idarubicin and Rilonacept.	Rheumatoid arthritis [FA20]	[94]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Idarubicin and Golimumab.	Rheumatoid arthritis [FA20]	[95]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Quetiapine.	Schizophrenia [6A20]	[60]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Aripiprazole.	Schizophrenia [6A20]	[79]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Iloperidone.	Schizophrenia [6A20]	[60]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Paliperidone.	Schizophrenia [6A20]	[60]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Amisulpride.	Schizophrenia [6A20]	[96]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Asenapine.	Schizophrenia [6A20]	[60]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Idarubicin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[97]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Idarubicin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[60]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Idarubicin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[60]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[61]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Pitolisant.	Somnolence [MG42]	[60]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[60]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[98]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Lenvatinib.	Thyroid cancer [2D10]	[60]
Elagolix	DMB2C0E	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Elagolix.	Uterine fibroid [2E86]	[63]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[99]
Propafenone	DMPIBJK	Moderate	Decreased clearance of Idarubicin due to the transporter inhibition by Propafenone.	Ventricular tachyarrhythmia [BC71]	[63]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Idarubicin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[60]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Idarubicin and Valganciclovir.	Virus infection [1A24-1D9Z]	[79]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
• [2] New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [8] Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
• [9] In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
• [10] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [11] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [12] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [15] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [16] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [17] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [18] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [19] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [20] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [21] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [22] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [23] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [24] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [25] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [26] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [27] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [28] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [29] The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
• [30] Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
• [31] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [32] Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
• [33] Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
• [34] ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
• [35] Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
• [36] Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
• [37] Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
• [38] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [39] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [40] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [41] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [42] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [43] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [44] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [45] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [46] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [47] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [48] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [49] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [50] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [51] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [52] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [53] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [54] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [55] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [56] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [57] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [58] Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
• [59] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [60] Canadian Pharmacists Association.
• [61] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [62] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [63] Multum Information Services, Inc. Expert Review Panel.
• [64] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [65] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [66] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [67] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [68] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [69] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [70] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [71] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [72] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [73] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [74] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [75] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [76] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [77] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [78] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [79] Cerner Multum, Inc. "Australian Product Information.".
• [80] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [81] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [82] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [83] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [84] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [85] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [86] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [87] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [88] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [89] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [90] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [91] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [92] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [93] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [94] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [95] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [96] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [97] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [98] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [99] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]